FRI0487 Apremilast is associated with long-term (4-YEAR) DAS-28 (CRP) remission and improvements in skin disease: results from a phase iii study in dmard/biologic-experienced patients with active psoriatic arthritis

Cj Edwards,J Crowley,M Paris,N Delev,L Teng,M Mcilraith,Fj Blanco,Ca Birbara

doi:10.1136/annrheumdis-2017-eular.3563

FRI0487 Apremilast is associated with long-term (4-YEAR) DAS-28 (CRP) remission and improvements in skin disease: results from a phase iii study in dmard/biologic-experienced patients with active psoriatic arthritis

Cj Edwards, J Crowley + Show 6 more

Open Access

https://doi.org/10.1136/annrheumdis-2017-eular.3563

Copy DOI

Journal: Annals of the Rheumatic Diseases	Publication Date: Jun 1, 2017
Citations: 3

Affiliation: University Hospital Southampton NHS Foundation Trust, Bakersfield College, Bristol-Myers Squibb (Switzerland), Complexo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica de A Coruña, University of Massachusetts Chan Medical School

#Celgene Corporation #Baseline Psoriasis Area And Severity Index + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundTreatment goals for long-term control of skin and joint symptoms in active psoriatic arthritis (PsA) include clinically important changes in DAS-28 (CRP), achievement of remission in DAS-28 (CRP), reduction in...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of the Rheumatic Diseases

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.